Halder, Amelie
Liesenfeld, Oliver
Whitfield, Natalie
Uhle, Florian
Schenz, Judith
Mehrabi, Arianeb
Schmitt, Felix C. F.
Weigand, Markus A.
Decker, Sebastian O.
Funding for this research was provided by:
Universitätsklinikum Heidelberg
Article History
Received: 9 March 2024
Accepted: 1 June 2024
First Online: 12 June 2024
Declarations
:
: Informed consent was obtained from all subjects involved in this study.
: Not applicable.
: German Clinical Trials Register: DRKS00023236, Registered 07 October 2020,
: This study was conducted in accordance with the Declaration of Helsinki and approved by the Ethics Committee of the Medical Faculty of Heidelberg (TrialCode No. S-693/2020, date of approval: 30 September 2020).
: OL and NW are employees and stock options holders of Inflammatix, Inc. FU was previously an employee of Inflammatix. SOD received scientific grants from Heidelberg Foundation of Surgery and B.Braun Foundation, Melsungen, Germany, as well as research support from SphingoTec GmbH and Inflammatic Inc. MAW received grants from Köhler Chemie, DFG and BMBF, consulting fees from B. Braun, Gilead, Mundipharma and Boehringer Ingelheim, and payment or honoraria for lectures, presentations, or educational events from MSD, Gilead, Shionogi, Pfizer and Beckman Coulter. He is also a patent owner (EP17185036.5 and EP17198330.7), has participated on advisory boards for MSD, Gilead, Shionogi, Biotest, Pfizer, Eumedica, SOBI and Beckman Coulter, is the vice-head of the German Sepsis Society and member of the scientific advisory council of PEG, and is cofounder of Delta Theragnostics. The following authors declare no conflicts of interest: JS, FCFS, AH, AM.